Brain Stem Glioma (DIPG): Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Brain stem gliomas encompass a heterogeneous spectrum of tumors arising in the midbrain, pons, or medulla oblongata — structures that collectively regulate vital functions including consciousness, cardiorespiratory control, and cranial nerve function. The clinical, molecular, and prognostic characteristics of brain stem gliomas vary dramatically between the two major categories. Diffuse intrinsic pontine glioma (DIPG) is the most common and most lethal brain stem tumor — arising predominantly in the pons (the largest segment of the brain stem) in children aged 5-10 years, accounting for approximately 80% of pediatric brain stem tumors and 10-15% of all pediatric central nervous system tumors; approximately 300 new cases occur in the United States annually. DIPG carries one of the worst oncological prognoses of any pediatric malignancy — median overall survival of only 9-11 months despite treatment, with fewer than 5% of children surviving beyond 5 years; essentially all children die of progressive disease. The WHO 2021 Classification of CNS Tumors reclassified DIPG as 'diffuse midline glioma, H3K27-altered, grade 4' — reflecting its defining molecular event (histone H3 K27M mutation, present in approximately 80% of DIPG cases), its diffuse rather than focal growth pattern, and its universal malignant behavior regardless of histological appearance. Focal brain stem gliomas — a distinct entity representing approximately 20% of pediatric brain stem tumors — arise in the midbrain tectum, medulla, or cervical-medullary junction; they are well-circumscribed, often pilocytic astrocytoma (WHO grade 1) with BRAF fusions; they grow slowly, may be surgically resectable or responsive to BRAF inhibitors, and carry a 5-year survival exceeding 70%. Clinical distinction between DIPG and focal gliomas is critical as management and prognosis differ fundamentally.

DIPG arises from a novel oncogenic mechanism distinct from cerebral hemisphere gliomas. The defining molecular event in DIPG is a missense point mutation in histone H3 — specifically lysine 27 to methionine substitution (K27M) — in the H3F3A gene (encoding the H3.3 histone variant, found in approximately 70% of DIPG cases) or in the HIST1H3B gene (encoding the H3.1 histone variant, found in approximately 10-20%). The H3K27M mutation exerts a dominant-negative effect on PRC2 (Polycomb Repressive Complex 2), blocking the trimethylation of H3K27 (H3K27me3) — a critical epigenetic mark for gene silencing — across the genome, causing widespread derepression of oncogenes and disruption of chromatin architecture. Additional somatic mutations co-occurring with H3K27M in DIPG: activating PDGFRA mutations or amplification (~30%), ACVR1 mutations (~20%, particularly in H3.1-mutated DIPG), TP53 mutations (~40%), and PIK3CA/PIK3R1 mutations (~15%), with distinct mutation patterns characterizing H3.3 vs H3.1 DIPG. DIPG occurs exclusively in the pons — not in other brain regions — reflecting the developmental origin of H3K27M mutations from pontine-specific progenitor cells (ventral pontine progenitors expressing PDGFRA) during a critical developmental window in childhood. All DIPG cases are sporadic — no hereditary predisposition syndromes, no environmental risk factors, and no known preventable causes have been identified. Focal brain stem gliomas: most harbor BRAF alterations — BRAF-KIAA1549 tandem duplication fusion (resulting in constitutive BRAF activation, approximately 60% of pilocytic astrocytoma), or BRAF V600E point mutation (enabling targeted therapy with BRAF inhibitors); some harbor IDH mutations (IDH-mutant diffuse gliomas); cervicomedullary gliomas may harbor H3.3 mutations or NF1-related alterations. Radiation therapy is the only established environmental risk factor for any childhood glioma.

The clinical presentation of DIPG is remarkably stereotyped, reflecting the anatomical functions of the pons — which houses multiple cranial nerve nuclei, long tract fibers (corticospinal, spinothalamic), and the reticular formation — and distinguishes DIPG from other pediatric brain tumors. The classic diagnostic triad of DIPG (present in approximately 90% of children at diagnosis): cranial nerve palsies — the most common initial symptom, reflecting pontine cranial nerve nuclei disruption; most commonly diplopia (double vision from CN VI/CN III palsy), facial nerve palsy (unilateral facial weakness, inability to close the eye fully — CN VII), and dysphagia (difficulty swallowing from CN IX/X dysfunction); less commonly, facial sensory loss (CN V), hearing loss (CN VIII), and dysarthria; ataxia — gait unsteadiness, limb coordination difficulty, and truncal instability from involvement of the cerebellar peduncles passing through the pons; children may have difficulty walking, frequent falls, and hand clumsiness; long tract signs — upper motor neuron features indicating corticospinal tract disruption: limb weakness (usually ipsilateral to the more involved side), increased muscle tone, hyperreflexia, extensor plantar responses (Babinski sign), and clonus. Symptom trajectory: the DIPG triad characteristically evolves rapidly — from first symptom to clinical diagnosis often occurring within 3-8 weeks, reflecting the aggressive diffuse growth of DIPG. Raised intracranial pressure (ICP): less prominent in DIPG than in supratentorial tumors because DIPG infiltrates rather than obstructs CSF pathways; significant headache and vomiting suggesting raised ICP indicate hydrocephalus from aqueductal compression. Squint (strabismus): frequently the first noticed sign, initially attributed to uncorrected refractive error; a non-paralytic strabismus in a school-aged child that is not improving should prompt neurological evaluation. Focal brain stem gliomas (cervicomedullary, midbrain tectum, medullary exophytic): cervicomedullary — neck pain, head tilt, lower cranial nerve palsies (CN IX-XII: dysphonia, dysphagia, tongue weakness), and long tract signs; midbrain tectum — Parinaud syndrome (upgaze palsy, convergence-retraction nystagmus, and light-near dissociation of pupils) with hydrocephalus; slow, progressive course.

MRI brain with and without gadolinium contrast is the definitive imaging modality and the clinical cornerstone of DIPG diagnosis. MRI characteristics of DIPG: diffuse T2/FLAIR hyperintensity involving the majority (at least 50-60%) of the cross-sectional area of the pons — typically arising from the central pons and expanding concentrically to engulf the entire pontine tegmentum; the tumor does not form a discrete mass with sharp borders but infiltrates diffusely through pontine tissue; contrast enhancement is variable and often minimal or absent (approximately 50% show no enhancement on T1 gadolinium — this distinguishes DIPG from metastases and other enhancing lesions); diffusion restriction is absent (unlike high-grade cerebral gliomas). MRI also characterizes: encasement of the basilar artery (lying anterior to the pons), extension into the midbrain or medulla, cerebellar peduncle involvement, extension into the cervical cord, and any exophytic component protruding into the fourth ventricle or cisterns. Stereotactic biopsy: now recommended by NCCN, SIOPE, and PBTC guidelines for the majority of newly diagnosed DIPG cases — particularly those enrolling in clinical trials — because H3K27M mutation status and co-occurring molecular alterations (ACVR1, PDGFRA, TP53) now meaningfully guide trial selection and correlate with clinical outcome; stereotactic pontine biopsy has a low complication rate (<3% permanent neurological deficit) at experienced centers with neuronavigation and intraoperative monitoring. H3K27M mutation detected by IHC (anti-H3K27M antibody) and/or sequencing; ACVR1 mutation (associated with H3.1 subtype, possibly more favorable response to ACVR1 inhibitors); PDGFRA alteration; and comprehensive DNA methylation array profiling. Radiological diagnosis alone (without biopsy) remains acceptable at centers without DIPG biopsy expertise when clinical and imaging features are unequivocal and the child is symptomatic; however, trial enrollment increasingly requires tissue. MRI spine: evaluates drop metastases along the leptomeningeal surfaces (present in approximately 5-10% at diagnosis). No formal TNM staging — disease extent is radiologically defined.

Focal radiotherapy is the only treatment proven to temporarily improve function and quality of life for DIPG — no treatment has demonstrated improved overall survival in randomized phase III trials. Standard radiotherapy: focal conformal external beam radiotherapy (EBRT) delivering 54 Gy in 30 fractions (1.8 Gy per fraction daily, 5 days/week, over 6 weeks) to the tumor and a small margin; IMRT (intensity-modulated radiotherapy) or proton beam therapy reduces integral dose to surrounding normal brain. Clinical benefit: approximately 70-80% of children experience meaningful neurological improvement and functional stabilization during and immediately after radiotherapy (reflecting reduction of peritumoral edema and partial tumor response); median duration of response approximately 3-6 months; median OS with radiotherapy 9-11 months. Hypofractionated radiotherapy (39 Gy in 13 fractions, 3 Gy/fraction over 3 weeks): achieves equivalent response duration and survival to standard fractionation and is increasingly used to reduce treatment burden and allow earlier access to experimental trials. ONC201 (TRC102, an oral dopamine receptor D2/D3 antagonist and ClpP mitochondrial protease activator): objective responses specifically in H3K27M-mutant diffuse midline gliomas — including objective tumor reductions confirmed on MRI, prolonged stable disease, and some durable responses exceeding 12 months; entering randomized Phase 3 trial (D3-1 trial: ONC201 with and without radiotherapy vs radiotherapy alone for newly diagnosed H3K27M+ DIPG); FDA granted Breakthrough Therapy designation. Systemic chemotherapy: no chemotherapy agent has improved DIPG survival in randomized trials despite extensive investigation — agents tested and proven ineffective include temozolomide, carboplatin, vincristine, CCNU (lomustine), bevacizumab, and numerous targeted agents. Ruxolitinib (JAK inhibitor) for ACVR1-mutated H3.1-DIPG: Phase 2 data showing benefit in this molecular subset (ACVR1/H3.1 DIPG has a distinct biology and may respond to ACVR1/BMP pathway inhibition). Convection-enhanced delivery (CED): intratumoral drug delivery bypassing the blood-brain barrier — infusing radiolabeled drugs (I-124/I-131 omburtamab), panobinostat, or CAR-T cells directly into the pons through implanted CED catheters — ongoing Phase 1-2 investigations. CART cells targeting GD2 (B7-H3 and EGFRvIII): early phase trials in DIPG showing encouraging signals. Focal brain stem gliomas (pilocytic, WHO grade 1): surgical resection for accessible cervicomedullary or exophytic lesions — potentially curative; BRAF V600E-mutated: dabrafenib plus trametinib; BRAF fusion: MEK inhibition with selumetinib or trametinib (SPRINT trial: 40% partial response in NF1-associated and sporadic pilocytic astrocytoma). Dexamethasone: used perioperatively and for symptomatic relief of peritumoral edema — tapered aggressively to minimize steroid complications. Palliative and supportive care: multidisciplinary palliative care involvement from diagnosis is strongly recommended — managing neurological symptoms, nutritional support (NG or gastrostomy tube), physiotherapy, and psychosocial support for the child and family.

Prognosis for brain stem gliomas differs dramatically between DIPG and focal brain stem gliomas. DIPG (diffuse intrinsic pontine glioma, WHO 2021: diffuse midline glioma H3K27-altered, grade 4) carries one of the worst prognoses in pediatric oncology — median overall survival with focal radiotherapy alone is approximately 9-11 months from diagnosis, and fewer than 5% of children survive beyond 5 years. Essentially all children die of progressive disease, typically from respiratory failure as the pons is progressively destroyed. The H3K27M mutation is universally associated with poor prognosis in midline gliomas. ONC201, which targets H3K27M-mutant diffuse midline gliomas, has shown objective tumor responses in early-phase trials with some patients achieving prolonged progression-free survival exceeding 12 months — representing the most promising development in DIPG management. Without treatment, progressive neurological deterioration leads to death within weeks to months; focal radiotherapy provides symptom control and extends median survival to approximately 9-11 months. Neurological function and quality of life are typically maintained for several months post-radiotherapy before progressive neurological deterioration from tumor regrowth. Focal brain stem gliomas carry dramatically better prognosis — pilocytic astrocytoma (WHO grade 1) of the midbrain or cervicomedullary junction achieves 5-year survival exceeding 70-80% with surgery alone or surgery plus targeted therapy. DIPG tumors that harbor BRAF V600E or NTRK fusions may respond to targeted therapy with meaningfully improved outcomes. Families of DIPG patients should be strongly encouraged to enroll in clinical trials and donate tissue through research platforms — understanding the biology of this disease is critically important for developing future effective treatments.

DIPG and most brain stem gliomas arise from sporadic somatic mutations (H3K27M in DIPG) without known preventable environmental causes. There are no established modifiable risk factors, and no lifestyle interventions are known to prevent these tumors. The most meaningful contribution to improving outcomes is research participation — all DIPG families should be encouraged to enroll in clinical trials and donate tissue through the Children's Brain Tumor Network, as tissue sharing has been essential to accelerating understanding of this disease. Families with children diagnosed with DIPG benefit from early palliative care integration alongside active treatment discussions, given the prognosis. Early recognition of presenting symptoms enables prompt diagnosis and enrolment in trials at a time when experimental treatments may be most effective.

The hallmark DIPG triad — double vision (diplopia) or facial droop due to cranial nerve palsy, unsteady gait (ataxia), and limb weakness or spasticity — in a school-aged child (typically 5-10 years) should prompt same-day or next-day referral to a paediatric neurologist. Because symptoms can progress rapidly over weeks, there should be no delay in obtaining brain MRI. A new squint (strabismus) in a child, particularly with accompanying gait instability or difficulty swallowing, requires urgent neurological evaluation. Focal brain stem gliomas in the medulla or cervical-medullary junction may present more slowly with head tilt, voice changes, or swallowing difficulties — these also require urgent imaging. Any child with a newly diagnosed brain stem lesion should be referred to a paediatric neuro-oncology centre with DIPG expertise and access to clinical trials, as standard treatment options are currently limited.